GSK's RSV vaccine meets main goal
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK pursues co-administration of RSV and shingles vaccines
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new hope.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
cidrap.umn56m
Over half of US kids infected with RSV in infancy, new data show
Of the eligible infants, 897 (53.4%) were infected with RSV in the first year of life and 783 (46.6%) were not. Active ...
RSV Can Be a Killer. New Tools Are Identifying the Most At-Risk Kids
RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...
The American Journal of Managed Care1d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
WGAL6d
Pulmonologist talks about RSV: Symptoms, who's most at risk, effectiveness of vaccine
A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...
WDRB22h
As flu season approaches, experts advise vaccination for COVID-19, RSV and the flu
The CDC recommends everyone ages 6 months and older get an updated COVID-19 and Flu vaccines. The RSV vaccine is recommended ...
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
Newcenter12d
Prevention tips to protect you and your family from RSV Season
RAPID CITY, S.D. - With fall approaching, not only will the days become darker and cooler, but cold and flu season will also ...
Free RSV vaccines for pregnant women could be coming next year — here's what you need to know
RSV is a highly infectious virus that is the most common cause of respiratory infections in children. A free vaccine could ...